Abstract
The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response. Recent evidence suggests that peroxisome proliferator-activated receptors (PPARs) exert their anti-inflammatory activities in vascular and immunological cell types such as endothelial cells, vascular smooth muscle cells and monocytes/macrophages. In these cells, PPARs regulate the gene expression of key proteins involved in the vascular inflammation contributing to atherogenesis. By modulating transcription of proinflammatory genes such as cytokines, chemokines, endothelial cell adhesion molecules and metalloproteinases, one can affect the events involved in atherogenesis, such as monocyte/macrophage and lymphocyte recruitment to the arterial wall and foam cell formation. Thus, PPAR agonists have emerged as a potential tool to modulate the inception and progression of atherosclerosis by exerting direct antiinflammatory and antiatherogenic actions at the level of the arterial wall. In this review, we will describe the current understanding of PPARs, the antiinflammatory activities of PPAR agonists and their proposed mechanisms of action.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 109-116 |
| Number of pages | 8 |
| Journal | Drug News and Perspectives |
| Volume | 16 |
| Issue number | 2 |
| DOIs | |
| State | Published - Mar 2003 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
Cite this
Modulation of vascular inflammation by PPARs. / Tham, Doris M.; Wang, Yi Xin; Rutledge, John C.
In: Drug News and Perspectives, Vol. 16, No. 2, 03.2003, p. 109-116.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Modulation of vascular inflammation by PPARs
AU - Tham, Doris M.
AU - Wang, Yi Xin
AU - Rutledge, John C
PY - 2003/3
Y1 - 2003/3
N2 - The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response. Recent evidence suggests that peroxisome proliferator-activated receptors (PPARs) exert their anti-inflammatory activities in vascular and immunological cell types such as endothelial cells, vascular smooth muscle cells and monocytes/macrophages. In these cells, PPARs regulate the gene expression of key proteins involved in the vascular inflammation contributing to atherogenesis. By modulating transcription of proinflammatory genes such as cytokines, chemokines, endothelial cell adhesion molecules and metalloproteinases, one can affect the events involved in atherogenesis, such as monocyte/macrophage and lymphocyte recruitment to the arterial wall and foam cell formation. Thus, PPAR agonists have emerged as a potential tool to modulate the inception and progression of atherosclerosis by exerting direct antiinflammatory and antiatherogenic actions at the level of the arterial wall. In this review, we will describe the current understanding of PPARs, the antiinflammatory activities of PPAR agonists and their proposed mechanisms of action.
AB - The activation of cells in atherosclerotic lesions leads to the release of proinflammatory molecules and the onset of a chronic inflammatory response. Recent evidence suggests that peroxisome proliferator-activated receptors (PPARs) exert their anti-inflammatory activities in vascular and immunological cell types such as endothelial cells, vascular smooth muscle cells and monocytes/macrophages. In these cells, PPARs regulate the gene expression of key proteins involved in the vascular inflammation contributing to atherogenesis. By modulating transcription of proinflammatory genes such as cytokines, chemokines, endothelial cell adhesion molecules and metalloproteinases, one can affect the events involved in atherogenesis, such as monocyte/macrophage and lymphocyte recruitment to the arterial wall and foam cell formation. Thus, PPAR agonists have emerged as a potential tool to modulate the inception and progression of atherosclerosis by exerting direct antiinflammatory and antiatherogenic actions at the level of the arterial wall. In this review, we will describe the current understanding of PPARs, the antiinflammatory activities of PPAR agonists and their proposed mechanisms of action.
UR - http://www.scopus.com/inward/record.url?scp=0037933426&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037933426&partnerID=8YFLogxK
U2 - 10.1358/dnp.2003.16.2.740244
DO - 10.1358/dnp.2003.16.2.740244
M3 - Article
VL - 16
SP - 109
EP - 116
JO - Drug News and Perspectives
JF - Drug News and Perspectives
SN - 0214-0934
IS - 2
ER -